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Background: Data on the psychosocial burden of human papillomavirus (HPV)-related diseases other than cervical
cancer are scarce. The objectives of this study were to measure and compare the psychosocial burden and the
impact on health-related quality of life (HRQoL) of HPV-related lower genital tract diseases and genital warts (GW)
using several generic and disease-specific instruments.
Methods: Overall, 842 individuals with normal cervical cytology (n = 241), borderline nuclear abnormalities and/or
mild dyskaryosis (n = 23), cervical intraepithelial neoplasia (CIN)1 (n = 84), CIN2/3 (n = 203), vulval intraepithelial
neoplasia (VIN)2/3 (n = 43), GW (n = 186) and a history of GW (non-current) (n = 62) were included. The generic
European Quality of Life Index Version 5D (EQ-5D) questionnaire was completed by patients with GW and VIN2/3.
Sexual functioning was evaluated using the Change in Sexual Functioning Questionnaire (CSFQ). Psychosocial
impact was measured in women using the HPV Impact Profile (HIP) questionnaire. HRQoL was assessed using a
GW-specific questionnaire, the Cuestionario Especifico en Condilomas Acuminados (CECA) (completed by patients
with GW and history of GW). For each instrument, scores were compared between groups using the Student's t-test.
In addition, utility loss due to GW and VIN2/3 was evaluated by comparing mean EQ-5D scores weighted by age
and sex with the UK general population normal values.
Results: A significant psychosocial impact was found in women diagnosed with HPV-related genital diseases,
particularly in those with GW. The health state of younger adults with GW was significantly impaired compared with
UK normal values (mean EQ-5D index score 0.86 vs 0.94, p < 0.001 for 18–24-year-olds; 0.87 vs 0.93, p = 0.030 for
25–34-year-olds). VIN2/3 was found to have a significant negative impact on sexual functioning, and women with
VIN2/3 had a highly impaired health state compared with women in the UK general population (weighted mean
EQ-5D index score 0.72 vs 0.89, p < 0.001; weighted mean Visual Analogue Scale score 62 vs 85, p < 0.001).
Conclusions: HPV-related lower genital tract lesions and GW significantly impair psychosocial wellbeing and
HRQoL. The psychosocial aspects of HPV-related diseases need to be considered when evaluating the potential
benefit of HPV vaccination.
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Approximately 70% of sexually active individuals will be
infected with human papillomavirus (HPV) during their
lifetime [1]. Most infections are asymptomatic and clear
spontaneously [2], but persistent infections with some
HPV types may lead to anogenital neoplasia and genital
warts (GW) [3,4].
The main burden of HPV-related diseases is due to
cervical cancer. HPV-related precancerous lesions of
the lower genital tract (e.g. cervical intraepithelial
neoplasia [CIN] grades 1/2/3 and vulval intraepithelial
neoplasia [VIN] grades 1/2/3) are also potentially
serious conditions, requiring repeated health care visits
for disease monitoring and treatment. Over the last
40 years, the incidence of VIN and vulval cancer has in-
creased in developed countries, predominantly among
women aged <50 years [5-8]. The incidence of GW has
also increased considerably in many European coun-
tries, including the UK [9,10]. GW are unsightly and
often cause discomfort, and only a minority of cases re-
solve without treatment. Treatment is usually lengthy
and painful, and often does not prevent recurrences
[3]. The increases in incidence of VIN, vulval cancer
and GW may be partially explained by increased HPV
transmission and infection rates due to changes in be-
haviour [11,12].
In Europe, two HPV genotypes (16 and 18) are respon-
sible for approximately 73% of cervical cancers [13] and
the majority of HPV-related vulval and vaginal cancers
[14]. HPV 6 and 11 are responsible for 90% of GW af-
fecting both men and women [3]. Primary prevention of
HPV-related diseases through HPV vaccination is rec-
ommended in many countries. Two prophylactic HPV
vaccines, Gardasil® (Sanofi Pasteur MSD, Lyon, France)
and Cervarix® (GlaxoSmithKline Biologicals, Rixensart,
Belgium), are available, which both protect against
precancerous lesions, including CIN1/2/3, VIN2/3, and
cervical cancer caused by HPV 16 and 18. In addition,
the quadrivalent vaccine Gardasil® also protects against
infection and disease caused by HPV 6 and 11, includ-
ing GW. Determining the impact of HPV-related dis-
ease on patients’ health-related quality of life (HRQoL)
is important to fully assess the value of HPV vaccin-
ation. Many studies have documented the psychosocial
burden associated with cervical cancer and its impact
on HRQoL [15-19] and some studies have evaluated
the impact of GW [20-25]. However, fewer studies have
quantified the impact of other HPV-related diseases
[26-30] or used an HPV-specific questionnaire.
The objective of the Papillomavirus ASsociated QUAl-
ity of Life (PasQual) study was to assess the psychosocial
burden and impact on HRQoL of HPV-related lower
genital tract diseases and GW in the UK using generic
and disease-specific instruments.Methods
Participants
Study participants were aged 18–64 years and included
women with normal cervical cytology, borderline nuclear
abnormalities and/or mild dyskaryosis, CIN1, CIN2/3
and VIN2/3, and women and men with GW or with a
history of GW. Participants included in the GW group
were recruited any time during a current episode of GW
(i.e. undergoing diagnosis and/or treatment of a GW
episode that was clinically present at the time of inclu-
sion in the study), whether this was a first episode or a
recurrence. Participants included in the history of GW
group were attending health care facilities for the follow-
up of a previous sexually transmitted infection (STI) and
had previously experienced an episode of GW that had
resolved ≥6 months before study enrolment. Participants
were made aware of their diagnosis and provided written
informed consent prior to administration of question-
naires. Exclusion criteria included any concomitant STI,
any concomitant condition that might have an impact
on the psychosocial burden of participants, and vaccin-
ation with an HPV vaccine.
Study design and procedures
This was a multicentre, observational, cross-sectional
study. Participants were recruited at 15 centres (six sec-
ondary care colposcopy and gynaecology clinics, five
genitourinary medicine clinics, two general practice
clinics and two family planning clinics) across the UK
between May 2008 and March 2009.
The protocol and other study documents were ap-
proved by the Multi-Centre Research Ethics Committee
for Wales (reference 07/MRE09/75), and local institu-
tional approvals were obtained as appropriate. The study
was conducted in accordance with the Declaration of
Helsinki, Good Epidemiological Practice guidelines [31],
and local regulations.
Basic demographic data, including age, sex, socioeco-
nomic status, current marital/relationship status, medical
history and clinical status, were collected at enrolment.
Four instruments were used to measure the patient’s
perspective: two disease-specific questionnaires (the
HPV Impact Profile [HIP] questionnaire [32] and the
Cuestionario Especifico en Condilomas Acuminados
[CECA] [33,34] and two generic questionnaires (the
European Quality of Life Index Version 5D [EQ-5D]
[35] and the Change in Sexual Functioning Question-
naire [CSFQ] [36]). The instruments used in each HPV
disease group are shown in Table 1.
The sample size calculation was based on the results
of the US validation study for the HIP questionnaire
[32], considering an anticipated response rate of 60%
[37], a two-sided t-test with 90% power to detect a sta-
tistically significant difference in HIP scores between the
Table 1 Patient-reported outcome instruments used in each group
Group Patient-reported outcome instrument
HIP CSFQ EQ-5D CECA
Normal cervical cytology ✓ ✓
Borderline nuclear abnormalities and/or mild dyskaryosis ✓ ✓
CIN1/2/3 ✓ ✓
VIN2/3 ✓ ✓ ✓
GW (women) ✓ ✓ ✓ ✓
History of GW (women) ✓ ✓ ✓
GW (men) ✓ ✓ ✓
History of GW (men) ✓ ✓
CECA, Cuestionario Especifico en Condilomas Acuminados; CIN, cervical intraepithelial neoplasia; CSFQ, Change in Sexual Functioning Questionnaire; EQ-5D,
European Quality of Life Index Version 5D; GW, genital warts; HIP, Human Papillomavirus Impact Profile; VIN, vulval intraepithelial neoplasia.
Ticks indicate that a given patient-reported outcome instrument was administered.
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bility considerations. A sample of 50 participants with
VIN2/3 and 200 in each of the other groups was defined.
Patient-reported outcome instruments
HIP
The HIP questionnaire is specifically designed to meas-
ure psychosocial burden in women with HPV-related
diseases and comprises 29 items grouped into seven psy-
chosocial dimensions: worries and concerns; emotional
impact; sexual impact; self-image; partner issues and
transmission; interactions with doctors; and health con-
trol and life impact [32]. Dimension scores and a total
burden score, all ranging from 0 to 100, are calculated
based on item scores. Higher scores indicate a greater
psychosocial impact of HPV.
CSFQ
Short versions of the CSFQ, a validated, sex-specific
questionnaire designed to measure the impact of dis-
eases and medication on sexual functioning, were used
[36], comprising 14 items grouped into five dimensions:
pleasure, desire/frequency, desire/interest, arousal/ex-
citement, and orgasm. Dimension scores and a total sex-
ual functioning score are calculated as the sum of item
scores. Lower scores indicate worse sexual functioning.
EQ-5D
The EQ-5D is a self-administered, generic, preference-
based instrument designed to measure the impact of dis-
ease on the general health state, and comprises the EQ-5D
index and the EQ Visual Analogue Scale (VAS) [35]. The
EQ-5D index requires participants to state the extent of
problems in five dimensions—mobility, self-care, usual ac-
tivities, pain/discomfort and anxiety/depression—with a
higher EQ-5D index score indicating a better general
health state. The EQ VAS requires participants to ratetheir current state of health on a scale of 0–100, with 0 in-
dicating the worst imaginable and 100 the best imaginable
health state.
CECA
The CECA is a validated, ten-item, self-administered
questionnaire designed specifically to measure the
HRQoL of individuals with GW [33,34]. CECA items are
grouped into two dimensions: emotional (six items) and
sexual (four items); a global score is derived from the
ten item scores. Scores range from 0 (worst HRQoL) to
100 (best HRQoL).
Data analysis
Women with normal cervical cytology were considered
as the reference group against which women with HPV-
related diseases were compared. As the CECA is specific
to GW, healthy participants having never experienced
GW are not able to answer the questionnaire and are
not a suitable comparator. Therefore, in the assessment
of CECA scores, participants with a history of GW were
used as the reference group. The Student’s t-test (HIP,
CSFQ and CECA) and analysis of variance (HIP and
CSFQ) were used for between-group comparisons of
questionnaire scores. Crude EQ-5D scores were de-
scribed for participants with GW and participants with
VIN2/3. Weighted mean EQ-5D scores were compared
with UK general population normal values [38] using
the Student’s t-test (data weighted according to the age/
sex distribution of the UK population). Age-stratified
comparisons of EQ-5D scores between participants with
GW and UK general population norms were also con-
ducted; due to low numbers of participants with VIN2/3,
age stratified data for VIN2/3 are not presented. A p
value ≤0.05 was considered statistically significant. All
statistical analyses were performed using SAS software
(version 9.1.3, SAS Institute, Inc., Cary, NC, USA).
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Study population
Of the 2502 individuals screened for the PasQual study,
1512 (60.4%) met all the screening criteria and 1272
(50.8%) were included in the study after confirmation of
diagnosis. Of these, 842 (66.2%) completed at least one
item of one or more questionnaires. Patients with VIN2/3,
GW and history of GW completed at least one item of the
EQ-5D or the CECA (n = 290). Overall, numbers in each
group were as follows: normal cervical cytology, n = 241;
borderline nuclear abnormalities and/or mild dyskaryosis,
n = 23; CIN1, n = 84; CIN2/3, n = 203; VIN2/3, n = 43;
GW, n = 186; and history of GW, n = 62 (Figure 1). The
mean age of study participants was 34 years (range 18–
64 years); the socio-demographic characteristics of study
participants are shown in Table 2.
Psychosocial burden assessment (HIP questionnaire)
Women with HPV-related disease had significantly
higher mean total HIP scores than women with normal
cervical cytology (Figure 2a, p < 0.001). Similar results
were observed for all HIP dimensions (p ≤ 0.001, for all
dimensions).Total screened
n=2502
Total pre-included
n=1512 (60.4%)
Total included
n=1272 (84.1%)
Included in at least one
analysis population
n=842 (66.2%)
Normal cervical cytology (n=241)
Borderline nuclear abnormalities (n=23)
and/or mild dyskaryosis
)48=n(1NIC
)302=n(3/2NIC
*)24=n(3/2NIV
)681=n(WG
History of GW (non-current) (n=62)
3/2NIV
WG
History 
CECA/EHIP/CSFQ analysis populations (n=841):
Figure 1 Flow chart of study populations. CECA, Cuestionario Especifico
CSFQ, Change in Sexual Functioning Questionnaire; EQ-5D, European Quali
rus Impact Profile; VIN, vulval intraepithelial neoplasia. * Of the 43 patients i
the HIP/CSFQ questionnaires; a different patient did not complete at leastWomen with GW had the highest mean total HIP
score (50.9 [standard deviation, SD: 18.3] vs 22.3 [SD:
11.5] for women with normal cervical cytology), and had
a significantly higher mean HIP score compared with
women with VIN2/3 (50.9 [SD: 18.3] vs 43.8 [20.2], p =
0.044). Mean total HIP score was similar in women with
GW and history of GW (50.9 [SD: 18.3] vs 45.8 [SD:
19.0], p = 0.166).
Mean dimension scores were similar for women with
HPV-related disease except for women with GW, who
had significantly higher mean scores compared with
women with VIN2/3 and women with a history of GW
for the following dimensions: partner issues and trans-
mission (58.7 [SD: 27.9] vs 27.6 [SD: 25.4], p < 0.001 for
VIN2/3 comparison; 58.7 [SD: 27.9] vs 35.0 [SD: 25.8],
p < 0.001, for history of GW comparison); sexual impact
(63.2 [SD: 32.5] vs 46.9 [SD: 30.9], p = 0.012, for history
of GW comparison) and self-image (62.7 [SD: 25.3] vs
48.8 [SD: 22.9], p = 0.003, for VIN2/3 comparison).
Sexual functioning assessment (CSFQ)
Women with HPV-related disease had similar mean total
CSFQ scores compared with women with normal cervical*)24=n(
)681=n(
of GW (non-current) (n=62)
Q-5D analysis populations (n=290):
990 not pre-included (39.6%)
(not all inclusion criteria met, participant refusal,
lack of time, participant unable to understand, other
reasons)
240 not included (15.9%)
(normal cervical cytology confirmed as borderline,
not eligible, withdrawal before reception of results,
missing study group)
430 not included in analysis populations (33.8%)
(discontinuation before questionnaire completion,
no questionnaire completed, questionnaire not
completed in appropriate time window, missing date
of biopsy for participants with CIN1 or CIN2/3)
en Condilomas Acuminados; CIN, cervical intraepithelial neoplasia;
ty of Life Index Version 5D; GW, genital warts; HIP, Human Papillomavi-
n the VIN2/3 group, one patient did not complete at least one item of
one item of the CECA/EQ-5D questionnaires.
Table 2 Socio-demographic characteristics of study participants
Normal
(n = 241)
Borderline*
(n = 23)
CIN1
(n = 84)
CIN2/3
(n = 203)
VIN2/3
(n = 42)
GW
(n = 186)
GW history
(n = 62)
Total
(n = 841)
Age in years
Mean (SD) 40.4 (10.1) 35.6 (9.0) 32.9 (9.6) 31.7 (8.1) 44.8 (10.0) 28.0 (9.2) 28.4 (7.8) 34.0 (10.6)
Sex, n (%)
Female 241 (100.0) 23 (100.0) 84 (100.00) 203 (100.0) 42 (100.0) 101 (54.3) 39 (62.9) 733 (87.2)
Male 0 0 0 0 0 85 (45.7) 23 (37.1) 108 (12.8)
Level of education, n (%)
Secondary education (5–7years of education) 109 (45.2) 8 (34.8) 25 (29.8) 66 (32.5) 17 (40.5) 57 (30.6) 17 (27.4) 299 (35.6)
Further education (≥8 years of education) 132 (54.8) 15 (65.2) 58 (69.0) 137 (67.5) 23 (54.8) 129 (69.4) 45 (72.6) 539 (64.1)
Other† 0 0 1 (1.2) 0 2 (4.8) 0 0 3 (0.4)
Employment status, n (%)
Employed full-time 95 (39.4) 12 (52.2) 42 (50.0) 104 (51.2) 16 (38.1) 97 (52.2) 38 (61.3) 404 (48.0)
Employed part-time 63 (26.1) 5 (21.7) 15 (17.9) 30 (14.8) 8 (19.0) 14 (7.5) 3 (4.8) 138 (16.4)
Retired 11 (4.6) 0 0 0 2 (4.8) 0 0 13 (1.5)
Student 4 (1.7) 1 (4.3) 8 (9.5) 12 (5.9) 1 (2.4) 45 (24.2) 10 (16.1) 81 (9.6)
Other‡ 68 (28.2) 5 (21.7) 19 (22.6) 57 (28.1) 15 (35.7) 30 (16.1) 11 (17.7) 205 (24.4)
Marital status, n (%)
Single 36 (14.9) 11 (47.8) 35 (41.7) 75 (36.9) 9 (21.4) 134 (72.0) 45 (72.6) 345 (41.0)
Married 138 (57.3) 5 (21.7) 25 (29.8) 60 (29.6) 21 (50.0) 10 (5.4) 1 (1.6) 260 (30.9)
Cohabiting 45 (18.7) 2 (8.7) 15 (17.9) 47 (23.2) 7 (16.7) 28 (15.1) 10 (16.1) 154 (18.3)
Divorced/separated/widowed 22 (9.1) 5 (21.7) 9 (10.7) 21 (10.3) 5 (11.9) 14 (7.5) 6 (9.7) 82 (9.8)
Sexual relationship status, n (%)
Current partner 210 (87.1) 15 (65.2) 59 (70.2) 165 (81.3) 33 (78.6) 117 (62.9) 35 (56.5) 634 (75.4)
No current partner 31 (12.9) 8 (34.8) 25 (29.8) 38 (18.7) 9 (21.4) 69 (37.1) 27 (43.5) 207 (24.6)
*Borderline nuclear abnormalities and/or mild dyskaryosis.
†Data missing or <5 years of education.
‡Includes unemployed, self-employed, housewife/husband, long-term sick leave, and other.
CIN, cervical intraepithelial neoplasia; GW, genital warts; SD, standard deviation; VIN, vulval intraepithelial neoplasia.
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lower mean total CSFQ score (Figure 2b, p < 0.001). Mean
dimension scores for women with HPV-related diseases
were similar to those for women with normal cervical cy-
tology, except for women with VIN2/3 who reported worse
scores for pleasure, desire/frequency, desire/interest and
arousal/excitement.
Participants with GW or a history of GW reported
similar sexual functioning: mean total CSFQ score for
women: 45.6 (SD: 8.3) vs 47.2 (SD: 7.3), p = 0.323; mean
total CSFQ score for men: 50.3 (SD: 5.9 vs 49.6 (SD:
4.8), p = 0.637, for GW and history of GW, respectively.QoL assessments
EQ-5D
Analysis for women with VIN2/3 The mean crude EQ-
5D index score was 0.74 (SD: 0.27) and mean crude VAS
score was 66 (SD: 19.9) for women with VIN2/3. Theyreported problems with anxiety/depression (64%), pain/
discomfort (45%), usual activities (29%), mobility (21%)
and self-care (7%).
After weighting the data for the age distribution of the UK
population, women with VIN2/3 had a significantly lower
mean EQ-5D index score (0.72 [SD: 0.27] vs 0.89, p < 0.001)
and mean VAS score (62 [SD: 18.9] vs 85, p < 0.001) than
women in the UK general population. A significantly greater
proportion of women with VIN2/3 reported problems with
all dimensions of the EQ-5D index (mobility, self-care, usual
activities, pain/discomfort and anxiety/depression) compared
with women in the UK general population, particularly for
the anxiety/depression dimension (73% [95% confidence
interval [CI]: 59.6–86.4] vs 21%, p < 0.001) (Figure 3a).
Analysis for participants with GW For women and
men with GW, the mean crude EQ-5D index score was
0.84 (SD: 0.16) and 0.89 (SD: 0.17), respectively, and the
mean crude VAS score was 75 (SD: 19.3) and 79 (SD:
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Figure 2 Analysis of psychosocial burden and sexual function assessments (crude data, women only). (a) Comparison of mean total HIP
scores. Higher scores indicate greater psychosocial impact. (b) Comparison of mean total CSFQ scores. Higher scores indicate better sexual
functioning. p value is from analysis of variance. Borderline, borderline nuclear abnormalities and/or mild dyskaryosis; CIN, cervical intraepithelial
neoplasia; CSFQ, Change in Sexual Functioning Questionnaire; GW, genital warts; HIP, Human Papillomavirus Impact Profile; Normal, normal
cervical cytology; SEM, standard error of the mean; VIN, vulval intraepithelial neoplasia.
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Figure 3 Comparison of EQ-5D health domains in participants with VIN2/3 and GW versus UK population norms (weighted data).
(a) Percentage of women with VIN2/3 reporting some or extreme problems with EQ-5D dimensions compared with a sex-matched sample from
the UK general population. p values are from χ2 tests and compare the VIN2/3 group with the UK general population. (b) Percentage of
participants (men and women) with GW reporting some or extreme problems with EQ-5D dimensions compared with the UK general population.
p values are from χ2 tests and compare the GW group with the UK general population. Error bars represent 95% confidence intervals. EQ-5D,
European Quality of Life Index Version 5D; GW, genital warts; VIN, vulval intraepithelial neoplasia.
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http://www.biomedcentral.com/1471-2458/13/106515.5), respectively. Problems reported by women were
with anxiety/depression (41%), pain/discomfort (27%),
mobility (7%), usual activities (4%) and self-care (2%).
Men reported problems with anxiety/depression (25%),
pain/discomfort (22%), usual activities (6%) and mobility
(2%).
After weighting the data for the age and sex distribu-
tion of the UK population, participants with GW had a
similar mean EQ-5D index score compared with the UK
general population (0.90 [SD: 0.13] vs 0.89, p = 0.633),
but a significantly lower mean VAS score (78 [SD: 14.8]
vs 85, p < 0.001). Overall, a significantly higher propor-
tion of participants with GW reported problems with
anxiety/depression compared with the UK general popu-
lation (41% [95% CI: 32.7–49.3] vs 19%, p < 0.001). By
contrast, significantly lower proportions of participants
with GW reported problems with mobility (4% vs 12%,
p = 0.007) and usual activities (4% vs 12%, p = 0.005)
compared with the UK general population (Figure 3b).
When age-stratified analyses were performed on crude
data, the youngest participants with GW had signifi-
cantly lower mean EQ-5D index scores compared with
UK norms (0.86 vs 0.94, p < 0.001 for 18–24-year-olds
and 0.87 vs 0.93, p = 0.030 for 25–34-year-olds). Evalu-
ation of mean VAS scores by age showed a statistically
significant difference versus UK norms in the younger
age groups only (76 vs 86, p < 0.001 for 18–24-year-olds;
80 vs 87, p = 0.004 for 25–34-year-olds; and 75 vs 87,
p = 0.050 for 35–44-year-olds).
CECA
Overall, participants with current GW had significantly
lower mean CECA emotional, sexual and global scores
than participants with a history of GW (non-current)
(p = 0.008, p = 0.020 and p = 0.006, respectively; Figure 4a).
After stratification by sex, similar differences were ob-
served in women (Figure 4b) but not in men (Figure 4c).
Discussion
At the time that the PasQual study was implemented, no
published study had simultaneously used several patient-
reported outcome instruments in individuals with HPV-
related diseases to capture the impact of these diseases
from a patient’s perspective. In the PasQual study, a sig-
nificant negative psychosocial impact was found in
women with a range of HPV-related diseases when com-
pared with women with normal cervical cytology. Add-
itionally, HPV-related external genital lesions (VIN2/3
and GW) were found to significantly impair HRQoL.
Differences in the age structure of the study groups
reflected the epidemiology of the respective disease. The
mean age of women with VIN2/3 was 45 years (range,
21–62 years). This is consistent with the fact that, histor-
ically, VIN2/3 and vulval cancer are associated witholder age and long-term persistent infection with high-
risk HPV, although both are now increasing in incidence
in younger women [6]. By contrast, participants with
GW or a history of GW had a mean age of 28 years
(ranges, 18–60 and 19–52 years, respectively), reflecting
the higher prevalence of GW in young adults than in
older individuals [39].
The mean total HIP score for women with normal cer-
vical cytology was 22.3, which was similar to mean total
scores reported in the studies of Pirotta et al. (25.8) [40]
and Wang et al. (28.2) [41], and about 8 points higher
than that observed in the initial validation study for this
instrument (14.4) [32]. The apparently elevated HIP
scores for women with normal cervical cytology may in-
dicate a negative impact of the cervical screening pro-
cedure itself, as observed in studies showing that women
undergoing routine gynaecological examinations may ex-
perience pain or discomfort, embarrassment, fear, worry,
nervousness and inconvenience [42,43]. However, in the
absence of a defined scale linking scores to clinically
relevant levels of impact, it is difficult to interpret abso-
lute score values. In our study, women with normal
cervical cytology were asked to complete the question-
naire when their test result was received. At this point,
they were more likely to feel relieved and less likely to
feel anxious than before receiving the result. Conse-
quently, we consider that these women were a suitable
reference group for the HIP questionnaire and CSFQ.
In the absence of another adequate comparison group,
men with a history of GW (non-current) were used as
the reference group for men with current GW in ana-
lyses of the CSFQ.
Compared with women with normal cervical cytology,
sexual functioning was significantly impaired only in
women with VIN2/3, as assessed by the CSFQ. This
finding may be partly related to age, as women with
VIN2/3 tended to be older than participants in the other
groups (mean age 44.8 vs 28.0–40.4 years, respectively).
However, age is unlikely to be the only factor affecting
sexual functioning. Women with VIN2/3 also had a
highly impaired health state, as assessed by the EQ-5D
index and VAS scores, compared with women in the UK
general population, with particular detriments being ob-
served in the anxiety/depression and pain/discomfort
dimensions.
Women with current GW experienced the greatest
negative psychosocial impact, as measured by the HIP
questionnaire, while the impact was generally similar
among women with other HPV-related diseases. These
observations are consistent with reports of other studies
that utilised the HIP questionnaire [32,40,41]. The mean
total HIP score for women with current GW was 2.3-
fold higher than the score for women with normal cer-
vical cytology, which is consistent with the 1.8–3.7-fold
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Figure 4 Analysis of CECA scores (crude data). (a) Comparison of mean CECA scores for male and female participants with GW versus those
with a history of GW. (b) Comparison of mean CECA scores for women and (c) for men with GW versus those with a history of GW. Higher
scores indicate a better health-related quality of life. p values are from the Student’s t-test and compare the GW group with the history of GW
group. Error bars represent standard error of the mean. CECA, Cuestionario Especifico en Condilomas Acuminados; GW, genital warts.
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mal cervical cytology in previous studies [32,40,41]. Di-
mensions that were particularly affected in women with
GW were sexual impact, self-image, and partner issues
and transmission. These dimensions have also been pre-
viously identified as being of particular concern in
women with GW [40,44]. Wang et al. observed similar
results for sexual impact and self-image, but there was
also a substantial impact of GW on worries and con-
cerns and less impact on partner issues and transmission
[41]. It is particularly notable that the impact of GW on
psychosocial burden appears to be greater than that of
diseases such as VIN2/3, which are considered to be
more severe from a clinical perspective and have been
shown to have a significant impact on sexual functioning
in previous studies [30,45]. The high psychosocial im-
pact of GW may be because they are visible and distres-
sing and associated with discomfort and feelings of
anxiety, depression, anger, fear of contagiousness, shame
and embarrassment [22,23,25,46]. In addition, treatment
of GW is long, painful and often unsatisfactory, with
high recurrence rates [3].
As assessed by the EQ-5D, participants with GW re-
ported problems with anxiety/depression more frequently
than the UK general population. This is consistent with
current knowledge regarding the experience of individuals
with GW in whom much of the associated morbidity ispsychological in nature [25]. By contrast, a lower propor-
tion of participants with GW in our study reported prob-
lems with mobility and usual activities than the UK
general population. This latter observation is likely to be
due to the age difference between the two populations as
participants with GW were younger overall than the UK
general population. The observed impact on the anxiety/
depression dimension (41% of participants with GW re-
ported problems) is similar to that reported in the recent
study of Woodhall et al. [24], in which 37% of participants
with GW reported problems in this dimension, and con-
sistent with the findings of other studies [20,22,23]. How-
ever, contrary to our observations, three of these studies
reported an increased level of pain/discomfort [22-24] and
one study reported a detrimental impact on usual activities
[22] among individuals with GW when compared with
general population samples.
Overall, participants with GW had a slightly impaired
health state, as assessed by the EQ VAS only, compared
with the UK general population. However, when focus-
sing on young adults (18–34 years of age), in whom the
prevalence of GW is the highest, both the mean EQ-5D
index and VAS scores were significantly reduced com-
pared with the UK population norms. In our study, the
weighted mean EQ-5D index and VAS scores for partici-
pants with GW were 0.90 and 78, respectively, which
are similar to those reported for the recent study of
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cant reduction in health state based on EQ-5D index
and VAS scores in individuals with GW when compared
with general population values has been reported in
other studies [22,23], in which the average reductions in
EQ-5D index score were 3.9 and 9.9 percentage points,
respectively, and the average reductions in VAS scores
were 13.9 and 6.0 percentage points, respectively.
Participants with current GW had a significantly im-
paired HRQoL, as assessed by CECA scores, compared
with participants with a history of GW (non-current). A
similar but lesser impact of GW on HRQoL has been
demonstrated in men in a study using the initial 22-item
CECA questionnaire [47]. When stratified by sex in the
present study, the difference between GW and history of
GW continued to be observed in women, but not in
men. In the PasQual study, female participants with GW
had significantly lower scores for the sexual domain of
the CECA than those with a history of GW, whereas
sexual functioning as assessed by the CSFQ was similar
between participants with GW and a history of GW.
This may seem contradictory, but it is important to note
that whilst the CECA evaluates the psychological aspects
of sexual life specifically related to GW, the CSFQ is a
generic instrument that evaluates functional aspects of
sexual life, which may explain these differences.
Despite several measures taken to try and increase study
recruitment (e.g. extension of study period and reminders
sent to participants), sample sizes were lower than
planned in some groups in our study. For participants
with borderline nuclear abnormalities and/or mild dyskar-
yosis, CIN1 and a history of GW, actual sample sizes were
23, 84 and 62 respectively, compared with the 200 planned
for each group. Several reasons may explain the low
numbers, including that many women screened for par-
ticipation in the CIN1 group did not have histological con-
firmation of CIN1 and were therefore not included, in the
other two groups, few individuals complied with the retro-
spective recruitment process and, in addition, individuals
with a history of GW recruited prospectively often had
other STIs, which was an exclusion criterion.
As each HPV-related disease is associated with specific
demographic characteristics, the UK general population
may not have been the best comparator to evaluate the
representativeness of our study population with regard
to each specific disease. Differences in the mean age be-
tween different HPV disease groups may have partially
impacted comparison across groups, particularly for sex-
ual functioning. The older age of the VIN2/3 group
compared with other groups may have impacted the
comparison of sexual functioning assessed by the CSFQ.
Furthermore, the younger age of the GW group com-
pared with the reference group could have masked a po-
tential negative impact of GW on sexual functioning.For the CECA, participants with a history of GW were
used as the reference group. Although this is not with-
out limitations, we considered it to be the most appro-
priate comparator group as the CECA cannot be
administered to individuals who have never experienced
GW. The validation study for the CECA compared indi-
viduals with an initial diagnosis of GW with a group of
individuals with persistent GW who were not receiving
current treatment [34]. Furthermore, factors such as the
number and size of lesions, which were measured in the
validation study [34], were not considered in the current
study. Finally, the study did not aim to collect clinical
data. Thus, while we observed statistical differences in
psychosocial burden and HRQoL between HPV disease
groups, we could not assess the extent to which these
differences were clinically meaningful.
Conclusions
This study demonstrates that HPV-related non-cancerous
and precancerous genital disease have a significant negative
impact on psychosocial wellbeing and HRQoL. The health
state of younger adults with GW, in whom the prevalence
of GW is known to be greatest, was significantly impaired
compared with UK normal values. VIN2/3 was found to
have a negative impact on sexual functioning and women
with VIN2/3 had a highly impaired health state compared
with women in the UK general population.
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